DBV Technologies to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
DBV Technologies (Euronext: DBV, Nasdaq: DBVT), a clinical-stage biopharmaceutical company, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for Monday, September 9, 2024, in New York City. Daniel Tassé, the company's Chief Executive Officer, will engage in a fireside chat at 3:00 pm ET.
Investors and interested parties can access a live webcast of the presentation through a provided link or via the Events section of DBV Technologies' Investors website. For those unable to attend live, a replay will be available on the company's website for 90 days following the event, offering extended access to the presentation content.
DBV Technologies (Euronext: DBV, Nasdaq: DBVT), un'azienda biofarmaceutica in fase clinica, ha annunciato la sua partecipazione alla 26ª Conferenza Annuale Globale sugli Investimenti H.C. Wainwright. L'evento si terrà lunedì 9 settembre 2024, a New York City. Daniel Tassé, amministratore delegato dell'azienda, parteciperà a un colloquio informale alle 15:00 ET.
Investitori e parti interessate possono accedere a un webcast dal vivo della presentazione tramite un link fornito o attraverso la sezione Eventi del sito web per investitori di DBV Technologies. Per coloro che non possono partecipare dal vivo, è disponibile una registrazione sul sito dell'azienda per 90 giorni dopo l'evento, offrendo un accesso prolungato ai contenuti della presentazione.
DBV Technologies (Euronext: DBV, Nasdaq: DBVT), una empresa biofarmacéutica en etapa clínica, ha anunciado su participación en la 26ª Conferencia Anual Global de Inversiones H.C. Wainwright. El evento está programado para el lunes 9 de septiembre de 2024, en la ciudad de Nueva York. Daniel Tassé, el director ejecutivo de la compañía, participará en una charla informal a las 3:00 pm ET.
Los inversores y partes interesadas pueden acceder a un webcast en vivo de la presentación a través de un enlace proporcionado o a través de la sección de Eventos en el sitio web de Inversores de DBV Technologies. Para aquellos que no puedan asistir en vivo, habrá una repetición disponible en el sitio web de la empresa durante 90 días después del evento, ofreciendo acceso extendido al contenido de la presentación.
DBV Technologies (Euronext: DBV, Nasdaq: DBVT), 임상 단계의 바이오 제약 회사가 H.C. Wainwright 제26회 연례 글로벌 투자 회의에 참여한다고 발표했습니다. 이 행사는 2024년 9월 9일 월요일에 뉴욕 시에서 열릴 예정입니다. 다니엘 타세 CEO가 오후 3시 ET에 불가마 대화에 참여합니다.
투자자와 이해관계자는 제공된 링크를 통해 또는 DBV Technologies의 투자자 웹사이트 이벤트 섹션을 통해 생중계 웹캐스트에 접속할 수 있습니다. 실시간 참석이 불가능한 분들을 위해, 이벤트 이후 90일 동안 회사 웹사이트에서 재생 가능한 녹화본이 제공되어 발표 내용에 대한 장기적인 접근이 가능합니다.
DBV Technologies (Euronext: DBV, Nasdaq: DBVT), une entreprise biopharmaceutique en phase clinique, a annoncé sa participation à la 26e Conférence Annuelle Mondiale sur les Investissements H.C. Wainwright. L'événement est prévu pour le lundi 9 septembre 2024, à New York. Daniel Tassé, le directeur général de l'entreprise, participera à une discussion informelle à 15h00 ET.
Les investisseurs et les parties intéressées peuvent accéder à une diffusion en direct de la présentation via un lien fourni ou via la section Événements du site web des investisseurs de DBV Technologies. Pour ceux qui ne peuvent pas assister en direct, une rediffusion sera disponible sur le site de l'entreprise pendant 90 jours après l'événement, offrant un accès prolongé au contenu de la présentation.
DBV Technologies (Euronext: DBV, Nasdaq: DBVT), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat seine Teilnahme an der 26. jährlichen globalen Investment-Konferenz von H.C. Wainwright bekannt gegeben. Die Veranstaltung findet am Montag, den 9. September 2024, in New York City statt. Daniel Tassé, der CEO des Unternehmens, wird um 15:00 Uhr ET an einem Fireside Chat teilnehmen.
Investoren und interessierte Parteien können über einen bereitgestellten Link oder über den Bereich Veranstaltungen auf der Investorenseite von DBV Technologies auf ein Live-Webcast der Präsentation zugreifen. Für diejenigen, die nicht live teilnehmen können, wird eine Wiedergabe auf der Unternehmenswebsite für 90 Tage nach der Veranstaltung zur Verfügung stehen, was einen erweiterten Zugang zu den Inhalten der Präsentation bietet.
- None.
- None.
Châtillon, France, September 4, 2024
DBV Technologies to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9, 2024, at 3:00 pm ET, in New York City.
A live webcast of the presentation can be accessed here, and will also be available on the Events section of the Company’s Investors website: https://dbv-technologies.com/investor-overview/events/
A replay will also be available on DBV Technologies’ website for 90 days after the event.
About DBV Technologies
DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV is currently focused on investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through EPIT® epicutaneous immunotherapy, the VIASKIN® patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of VIASKIN® peanut patch in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).
DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing one ordinary share) are traded on the Nasdaq Stock Market (Ticker: DBVT).
For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn.
Investor Contact
Katie Matthews
DBV Technologies
katie.matthews@dbv-technologies.com
Media Contact
Angela Marcucci
DBV Technologies
angela.marcucci@dbv-technologies.com
VIASKIN® and EPIT® are registered trademarks of DBV Technologies.
Attachment
FAQ
When is DBV Technologies (DBVT) participating in the H.C. Wainwright Global Investment Conference?
Who will represent DBV Technologies (DBVT) at the H.C. Wainwright conference?
What type of presentation will DBV Technologies (DBVT) give at the H.C. Wainwright conference?
At what time is DBV Technologies' (DBVT) presentation at the H.C. Wainwright conference?
How can investors access DBV Technologies' (DBVT) presentation at the H.C. Wainwright conference?
